MycoBank® is F2G's validated platform technology for the identification of essential genes in Aspergillus fumigatus. Advances in genomics and bioinformatics allow for the translation of this information across fungal genomes thereby identifying viable drug targets for the development of new anti-fungal agents.

The identification of genes necessary for the survival and growth of A. fumigatus is challenging. Traditional gene disruption or gene knockout methods are inappropriate because the organism has only one copy of each individual gene and disruption of essential genes would render the organism non viable.
The MycoBank® process involves the random disruption of individual genes within the A. fumigatus genome followed by the identification of those genes that are essential for the survival and growth of the organism. This technology permits the precise identification of the genes essential to the survival of the fungus, without the need for any structural information or with any preconceptions as to gene function.
By using MycoBank® derived gene targets and stringent validation steps we deliver HTS screens based on genes that fit the clinical need for broad spectrum anti-fungal agents. Our essential-gene to HTS output is exceptionally fast, scheduled for 36 weeks.